Source comparison
Hexarelin Results Timeline: Research Protocol Comparison
Understanding how dosing schedules, administration routes, and subject variables alter the hexarelin results timeline is critical for protocol design. The table below distills peer-reviewed findings into actionable comparisons. Daily Dosing (No Cycling) Peak G
This comparison does not assign a generated winner or score.
- Understanding how dosing schedules, administration routes, and subject variables alter the hexarelin results timeline is critical for protocol design. The table below distills peer-reviewed findings into actionable comparisons.
- Daily Dosing (No Cycling)
- Peak GH elevation 15–20× baseline first week
- IGF-1 rises 30–50% by week 4; receptor desensitization begins week 5–6
- Lean mass plateau by week 10; diminishing GH response limits late gains
- Effective for short studies (≤6 weeks); long protocols require cycling to avoid tachyphylaxis
- 5-On / 2-Off Cycling
- GH pulses maintain 12–18× baseline throughout 12 weeks
- IGF-1 elevation sustained at 40–55% above baseline without decay
- Lean mass and collagen gains continue through week 16; receptor sensitivity preserved
- Superior for chronic research; prevents receptor downregulation while maintaining anabolic signaling
- Subcutaneous Injection
- GH peaks at 30–40 minutes; bioavailability ~85%
- Standard IGF-1 timeline (week 2–4 upregulation)
- Full tissue remodeling by week 12–16 in most endpoints
- Gold standard for research; predictable pharmacokinetics and highest bioavailability
- Oral Administration
- Minimal GH response; poor bioavailability (<10%) due to gastric degradation
- Negligible IGF-1 upregulation; insufficient for anabolic endpoints
- No detectable chronic-phase outcomes in published models
- Not viable for GH/IGF-1 research; hexapeptide structure is unstable in acidic pH
- Young vs Aged Subjects
- Aged subjects show 40–60% lower peak GH vs young at same dose
- IGF-1 response delayed 1–2 weeks in aged models; lower absolute elevation
- Lean mass and bone gains smaller in aged subjects but still statistically significant by week 16
- Age-related GH resistance requires dose adjustment; chronic outcomes achievable but attenuated
- Low Dose (50–100 mcg/kg)
- GH elevation 6–10× baseline
- Modest IGF-1 rise (15–25%); slower lean mass accretion
- Detectable but smaller chronic gains; suitable for long-term safety studies
- Useful for metabolic research with lower desensitization risk
- High Dose (200–400 mcg/kg)
- GH elevation 15–25× baseline; dose-dependent ceiling effect above 400 mcg/kg
- Rapid IGF-1 upregulation (50–70%); earlier tissue response but faster receptor desensitization
- Larger early gains but plateau by week 8–10 without cycling; higher adverse event risk
- Maximizes early outcomes; requires cycling or dose tapering to sustain